Fresenius Kabi USA

Vermont New Product Launch R	eport	
NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
	m (m :1: 1)	
65219-0590-04	Tyenne (Tocilizumab-aazg) intravenous infusion 80mg/4 ml	4/17/2024
	Tyenne (Tocilizumab-aazg) intravenous infusion 200mg/10	
65219-0592-10	ml	4/17/2024
	Tyenne (Tocilizumab-aazg)	
65219-0594-20	intravenous infusion 400mg/20 ml	4/17/2024

WAC AT INTRODUCTION	MARKETING PRICING PLAN	MARKETING PRICING NONPUBLIC
	Tyenne has traditional marketing tactics consisting of F2F HCP promotion, as well as field-based teams (incl. sales) to assist with pull-through.	
\$ 391.68	Pricing is 26% below Actemra's WAC (Competitor product).	Y, NonPublic
	Tyenne has traditional marketing tactics consisting of F2F HCP promotion, as well as field-based teams (incl. sales) to assist with pull-through.	
\$ 979.20	Pricing is 26% below Actemra's WAC (Competitor product).	Y, NonPublic
	Tyenne has traditional marketing tactics consisting of F2F HCP promotion, as well as field-based teams (incl. sales) to assist with pull-through.	
\$ 1,958.40	Pricing is 26% below Actemra's WAC (Competitor product).	Y, NonPublic

ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR	PRIORITY REVIEW INDICATOR
Rheumatoid Arthritis: 1.5M adults Giant Cell Arthritis: 230K adults Juvenile Idiopathic Arthritis (Includes subgroups: Systemic Juvenile Idiopathic Arthritis & Polyartiular Juvenile Arthritis: 294K children	N	N
Rheumatoid Arthritis: 1.5M adults Giant Cell Arthritis: 230K adults Juvenile Idiopathic Arthritis (Includes subgroups: Systemic Juvenile Idiopathic Arthritis & Polyartiular Juvenile Arthritis: 294K children	N	N
Rheumatoid Arthritis: 1.5M adults Giant Cell Arthritis: 230K adults Juvenile Idiopathic Arthritis (Includes subgroups: Systemic Juvenile Idiopathic Arthritis & Polyartiular Juvenile Arthritis: 294K children	N	N

T

Τ

ľ

ACQUISITION DATE	ACQUISITION PRICE	ACQUISITION PRICE NONPUBLIC
N/A	N/A	N/A
N/A	N/A	N/A
	,	,
N/A	N/A	N/A

ACQUISITION PRICE COMMENT	GENERAL COMMENTS	
N/A	N/A	
,		
N/A	N/A	
N/A	N/A	